Outcome Capital has hired Donald D Haut as a Senior Advisor for its rapidly growing Boston area-based life sciences practice.
Haut is Managing Director for Haut Capital, which he started in 2014, and currently serves on the Board of Directors for three health care companies: MiMecore Therapeutics, Arthrosurface, and Xiros. Prior, he was Vice President for New Business Ventures at The Medicines Company, where he was responsible for leading that company’s deal to license Alnylam’s PCSK9 inhibitor. Previously, he was the Senior Vice President for Strategy and Business Development at Smith and Nephew's Advanced Surgical Devices Division, where he was responsible for all strategy development, M&A and licensing activities, and also built and ran Smith & Nephew's Women's Health business. Haut also previously held similar roles at 3M, JSB Partners and McKinsey and Company. He obtained his MBA at Washington University's Olin School of Business, his PhD in Molecular Biology at the University of Missouri-Columbia, and his undergraduate degree at the College of Wooster.
“Over the course of my career leading transactions in the life sciences industry, I’ve had many opportunities to witness the thoughtfulness and integrity with which the team at Outcome Capital conducts their business,” says Haut. “I was delighted to be asked to join this respected team, and especially drawn to their approach of building long-term, lasting value for clients.”
Dr Oded Ben-Joseph, Managing Director at Outcome Capital, says: “Our strategic approach to value enhancement, including the ability to carve out a clear path to liquidity for our clients, relies on the significant corporate and operational experience of our life sciences group. We are delighted to welcome Don to the Outcome team. His deep domain expertise across multiple disciplines in the pharmaceutical, biotech, and medical device segments, coupled with his transactional expertise, is unique and will complement Outcome’s entrepreneurial culture to the benefit of our clients.”